InspireMD (NSPR) Gets a Buy Rating from H.C. Wainwright

By Carrie Williams

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on InspireMD (NSPRResearch Report) today and set a price target of $5. The company’s shares closed last Monday at $2.22, close to its 52-week low of $1.90.

Bernardino noted:

“Our $5 PT was derived by using a 25% weighted-average cost of capital to discount free cash flows we project 2019-2030, and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then ascribing a 1% terminal growth rate and 75% probability of.”

According to, Bernardino ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.9% and a 28.9% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Innovus Pharmaceuticals Inc, Miragen Therapeutics Inc, and ENDRA Life Sciences Inc.

InspireMD has an analyst consensus of Moderate Buy, with a price target consensus of $5.

See today’s analyst top recommended stocks >>

Based on InspireMD’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.21 million. In comparison, last year the company had a GAAP net loss of $627K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

InspireMD, Inc. is a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions.